As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
We are living in a time of extraordinary cognitive convenience and that isn’t always a good thing. AI isn’t the real risk to leadership — shallow thinking is.
Mikko Hyppönen is one of the most recognizable faces of the cybersecurity industry. After fighting computer viruses, worms, and malware, for more than 35 years, he tells TechCrunch why he is now working on systems to stop killer drones.